Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation
ORLANDO, FL / ACCESS Newswire / August 5, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI), today announced that it has executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota Biosciences, LLC ("Xycota"), a preclinical biotechnology platform engineering non-psychoactive, precision-targeted therapeutics to physically repair brain circuitry and restore synaptic connectivity.
Xycota is advancing a transformative biological interface designed to physically repair damaged neural networks in catastrophic neurodegenerative diseases. By utilizing proprietary fungal-derived exosome delivery systems, Xycota's lead candidate, XYCO-01, directly upregulates the BDNF-TrkB neuroplasticity signaling pathway while bypassing first-pass liver metabolism and hallucinogenic receptor activation. This paradigm-shifting approach decouples therapeutic neural restoration from psychedelic side effects, establishing a standardized, controllable mechanism for structural brain repair.
Key Regulatory & Growth Catalyst: Pending FDA Orphan Drug Designation
Xycota has formally applied for Orphan Drug Designation (ODD) with the U.S. Food and Drug Administration (FDA) for XYCO-01 in its primary indication, Frontotemporal Dementia (FTD). Official issuance of the ODD status is expected shortly. Upon designation and approval, ODD status provides seven years of U.S. market exclusivity, tax credits for qualified clinical testing, and regulatory fee exemptions, greatly accelerating the clinical and commercial development roadmap.
Cutting-Edge Scientific Foundation & Platform Synergy
Xycota's platform is anchored by peer-reviewed mechanistic evidence published in the Nature Portfolio journal Neuropsychopharmacology (Trezza, Hausman, et al., 2026 Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway, demonstrating that synaptic restoration and cognitive improvement can be achieved by modulating intrinsic BDNF/TrkB growth pathways. Xycota's pipeline is led by Co-Founder & Chief Scientific Officer Dr. Marvin S. Hausman, MD, who brings over 50 years of CNS drug development experience, 6 successful FDA NDAs, and a proven track record of commercial exits.
Following the initial lead indication in Frontotemporal Dementia, the platform offers rapid expansion into Amyotrophic Lateral Sclerosis (ALS), mild traumatic brain injury (mTBI), and broader neurodegenerative conditions.
"Executing this LOI to acquire 100% of Xycota Biosciences marks a defining milestone in NexTel Medical's corporate development and growth trajectory," stated Matthew Dwyer, President and Chief Executive Officer of NexTel Medical Corp. "Xycota's cutting-edge exosome delivery platform addresses immense unmet clinical needs in Frontotemporal Dementia and ALS where no restorative therapies currently exist. Combining Xycota's breakthrough neuro-restoration architecture with NexTel's commercial infrastructure creates an extraordinary, value-generative catalyst for our shareholders."
About Xycota Biosciences, LLC
Xycota Biosciences, LLC is a precision biotechnology company engineering exosome-delivered neuroplasticity therapeutics to repair brain circuitry. Anchored by peer-reviewed science and institutional leadership, Xycota is building a scalable translational platform targeting FTD, ALS, and neurodegenerative disorders. For more information, visit https://xycota.com/ and connect on LinkedIn at https://www.linkedin.com/company/xycota-biosciences.
About NexTel Medical Corp.
NexTel Medical Corp. is a medical technology and biotechnology enterprise focused on acquiring, integrating, and commercializing high-impact medical platforms, novel therapeutic delivery technologies, and healthcare innovations.
Media & Investor Contacts:
NexTel Medical Corp.
Investor Relations & Corporate Communications
Email: ir@nextelmedical.com
Website: www.nextelmedical.com
Xycota Biosciences, LLC
Brad Listermann, President & Co-Founder
Email: info@xycota.com
Website: https://xycota.com/
SOURCE: NexTel Medical Corp
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nextel-medical-corp.-executes-letter-of-intent-to-acquire-100-of-xyco-1201772
